T6358

1-Azakenpaullone (azakenpaullone) is a potent and selective GSK-3β inhibitor with IC50 of 18 nM, >100-fold selectivity over CDK1/cyclin B and CDK5/p25.

Tubulin polymerization-IN-21 is an inhibitor of microtubulin polymerization that disrupts cell integrity and affects glucose metabolism, and has anticancer effects.

JAK-IN-20 is a potent, orally active, broad-based JAK inhibitor, effective on JAK1 (IC50: 7 nM), JAK2 (IC50: 5 nM), and JAK3 (IC50: 14 nM), exhibiting excellent pharmacokinetic and anti-inflammatory activity in vivo.

Estrogen receptor antagonist 1 is a potent inhibitor of the estrogen receptor, demonstrating research potential in breast cancer disease.

RET-IN-11 is a potent and selective RET inhibitor that acts on RET (IC50: 6.20 nM) and RETV804M (IC50: 18.68 nM). RET-IN-11 induces apoptosis and exhibits anti-proliferative and migratory effects in LC-2/ad cells.

HCV-IN-37 is a potent inhibitor of HCV. HCV-IN-37 is able to persist in rat plasma after oral administration to rats at a single dose of 15 mg/kg. The high potency of the active derivative HCV-IN-37 is mainly driven by the inhibition of the entry phase of the virus.

Zika virus-IN-1 is an inhibitor of Zika virus (EC50: 1.56 μM).

Anticancer agent 46 is a potent and selective anticancer agent that induces apoptosis. anticancer agent 46 exhibits cytotoxic effects in cancer cells and shows low toxicity to activated lymphocytes of human blood.

Antibacterial agent 89 is a potent antibacterial compound that interferes with bacterial transcription, exhibits anti-clostridial effects, and inhibits the release of cytotoxins and β'CH-σ interactions.

CX-6258 hydrochloride hydrate is a potent, selective inhibitor of pan-Pim kinase, targeting Pim-1 (IC50: 5 nM), Pim-2 (IC50: 25 nM), and Pim-3 (IC50: 16 nM).